
Andrew Kuykendall, MD, discusses the rationale behind choosing to evaluate fedratinib in a phase 2 study for patients with atypical chronic myeloid leukemia, chronic neutrophilic leukemia, MDS/MPN-unclassifiable, and MDS/MPN-ring sideroblasts and thrombocytosis.



















